title: The effect of antifungal treatment on the vaginal flora of women with vulvo-vaginal yeast infection with or without bacterial vaginosis.
abstract: Antibacterial therapy may enhance the risk of symptomatic vulvo-vaginal candidosis in susceptible women. We addressed the question whether oral antifungal treatment for vulvo-vaginal candidosis also influences the bacterial vaginal microflora. One hundred and forty-two patients with a culture-proven acute episode of recurrent vulvo-vaginal candidosis (RVC) were treated with fuconazole according to the ReCiDiF regimen (induction dose of 600 mg orally per week followed by 200 mg per week) or with a single dose of 200 mg pramiconazole, a new potent oral triazole. At inclusion, 1 week and 1 month after the end of antifungal treatment, the bacterial microflora was assessed by microscopy of vaginal fluid to detect lactobacillary grades and bacterial vaginosis (BV). The presence of BV was studied in these patients with vulvo-vaginal candidosis after treatment with antifungal medication. At the start of oral antifungal treatment, 6.3% of women with Candida were co-infected with BV. Of the BV-negative women, 10 out of 133 (8%) developed BV after 1 week and after 1 month 8 of them (7%) were still BV-positive. Although no patients received antibacterial treatment at any moment of the study, 6 out of 9 (66%) of the women with Candida and BV at inclusion no longer had BV 1 week after antifungal treatment and 6 out of 7 (86%) lacked BV after 1 month. Treatment with antifungals may have a beneficial effect on women with concurrent BV, but does not prevent BV from occurring in BV-negative women with Candida vaginitis.
authors.affiliation: Clinical Research Center Femicare, Lombardstraat 28, 3300, Tienen, Belgium. gilbert.donders@femicare.net
authors.forename: G
authors.initials: G
authors.lastname: Donders
authors.forename: G
authors.initials: G
authors.lastname: Bellen
authors.forename: J
authors.initials: J
authors.lastname: Ausma
authors.forename: L
authors.initials: L
authors.lastname: Verguts
authors.forename: J
authors.initials: J
authors.lastname: Vaneldere
authors.forename: P
authors.initials: P
authors.lastname: Hinoul
authors.forename: M
authors.initials: M
authors.lastname: Borgers
authors.forename: D
authors.initials: D
authors.lastname: Janssens
mesh_terms: D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001419:Bacteria / Q000254:growth & development*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D016585:Vaginosis, Bacterial / Q000139:chemically induced*
chemical_list: D000935:Antifungal Agents; D007093:Imidazoles; D014230:Triazoles; C482452:pramiconazole; D015725:Fluconazole